The G1 portal ensures that the Secretary of Health and Environment Surveillance of the Ministry of Health, Ethel Maciel, confirmed the start of the crusade that will focus, at this time, on insecure groups such as people with HIV/AIDS and professionals who work in places of exposure to the virus.
With 47,000 doses available in the National Immunization Program for use in the population, the inoculation scheme indicates two servings for each person.
The portfolio highlights in the report distributed to states and municipalities that the vaccination services must guarantee the complete scheme to the target population.
People with HIV/AIDS who have an immune status identified by a CD4 T cell count of less than 200 cells in the last six months can be immunized.
The condition of low immunity increases the risks of aggravation of the disease.
According to the ministry, this audience currently represents about 16,000 people throughout the country.
Professionals who work in laboratories in contact with the virus will also be immunized, as a preventive measure.
For pre-exposure vaccination, an interval of 30 days is recommended with any pre-administered medication.
In addition, vaccination is planned for people who had direct contact with body fluids and secretions of suspected or confirmed cases of the disease, as post-exposure prophylaxis.
In such situations, whose main objective is to block transmission, the recommendation is that it be applied regardless of the previous administration of any immunizer.
Also called Jynneos, Imvamune or Imvanex, the MVA-BN vaccine is produced by the Danish company Bavarian Nordic, being one of the main immunizers marketed and in use in part of Europe and the United States.
The latest epidemiological data from the WHO suggest that the outbreak is coming to an end in the European region and slowing down in the Americas, where human-to-human transmission occurs.
From January 2022 to February 27 of this year, a total of 86,173 cases and 100 deaths were confirmed by laboratory in 110 countries. The Health portfolio ensures that the current epidemiological scenario presents a progressive decline in Brazil, where 10,800 infections and 15 deaths are registered.
npg/ocs
